Drug czar: Mayfield in 'clear violation'
Sprint Cup driver Jeremy Mayfield's explanation -- that two allowed medications may have combined to result in a failed drug test -- isn't plausible, NASCAR's substance abuse policy administrator told USA Today.
"What we have is a clear violation of policy," David Black said, according to the newspaper. "In my many years of experience, I have never seen a violation like this due to the combination of over-the-counter or prescription products."
Black, whose Tennessee-based Aegis Labs runs NASCAR's drug-testing program, wouldn't divulge what drug Mayfield tested positive for, only saying it was "a drug of concern," the report said.
Mayfield became the first Cup driver to be suspended under the first-year policy.
On Saturday, he raised in a statement the possibility that "the combination of a prescribed medicine and an over the counter medicine reacted together and resulted in a positive drug test."
Mayfield, who did not qualify for Saturday night's Cup race at Darlington Raceway, received a positive random test the previous weekend at Richmond International Raceway.
He also failed a subsequent second test from the same sample. The results of that test were given to the governing body at noon and announced at a Saturday night news conference.
There is no appeal process.
"My doctor and I are working with both Dr. Black and NASCAR to resolve this matter," Mayfield's statement said.
Information from ESPN.com's David Newton was used in this report.
MORE RACING HEADLINES
- Hamlin's crew chief Grubb suspended 6 races
- Chase drivers can't attend Homestead tire test
- Gordon passes Kahne for fifth Brickyard win
- Edwards, Roush parting ways after season